Research for a vaccine to fight against coronavirus is speeding up… After several clinical trials in animals this Spring, the Institut Pasteur has announced with their scientific head Christophe d’Enfert to our peers at Le Point, that a first vaccine will be tested in humans from July, in “90 volunteers in France and Belgium”. A first candidate developed in partnership with pharmaceutical MSD group and tested throughout a “first clinical phase”.
The conception of this first vaccine is far from being unknown and has already proven its worth: “We will use an attenuated strain from the measles virus, especially used to vaccinate against measles, and which genetic heritage has been modified so that it can products the Spike protein enabling coronavirus to enter our cells” Institut Pasteur scientific head says. Last vaccine to have been conceived with the same method: the vaccine to fight against chikungunya, currently in phase 3 of testing, last stage before being put on the market.
The goal of this first test in humans is to enable “both to assess its innocuity in human beings and its capacity to induce to an immune response” Christophe d’Enfert explains. If tests are good and the different clinical phases go on smoothly, with a viable vaccine at the end, it could be commercialized for “the first 2021 semester”. Whatever happens, other vaccines are being studied across the world and could enter in clinical testing phase just as quickly.
A race to be the first ones to commercialize their vaccine the Institut Pasteur does not seem to be willing to run, without yet taking all their time: “The idea is not to be the 30th on the market, but in the first five” the scientific head says. Remember, slow and stead wins the race.